Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

[1]  J. Breza,et al.  The Incidence of Tumours in Renal Transplant Recipients with Long-Term Immunosuppressive Therapy , 2004, International Urology and Nephrology.

[2]  Napoleone Ferrara,et al.  The role of vascular endothelial growth factor in pathological angiogenesis , 2004, Breast Cancer Research and Treatment.

[3]  Liliana Attisano,et al.  Synergistic Cooperation between Hypoxia and Transforming Growth Factor-β Pathways on Human Vascular Endothelial Growth Factor Gene Expression* , 2001, The Journal of Biological Chemistry.

[4]  W. Falk,et al.  A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. , 2001, Cancer research.

[5]  J. Palmblad,et al.  Angiogenesis Research: Guidelines for Translation to Clinical Application , 2001, Thrombosis and Haemostasis.

[6]  N. Rahimi,et al.  Identification of Tyrosine Residues in Vascular Endothelial Growth Factor Receptor-2/FLK-1 Involved in Activation of Phosphatidylinositol 3-Kinase and Cell Proliferation* , 2001, The Journal of Biological Chemistry.

[7]  L. Devy,et al.  Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. , 2001, Cancer research.

[8]  M. Hendrix,et al.  Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta. , 2001, American journal of physiology. Heart and circulatory physiology.

[9]  M. Hendrix,et al.  Erratum: Mechanisms of coronary angiogenesis on response to stretch: Role of VEGF and TGF-β (American Journal of Physiology - Heart and Circulatory Physiology (February 2001) 280 (H909-H917)) , 2001 .

[10]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[11]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[12]  O. Volpert,et al.  Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[14]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[15]  Barry D Kahan,et al.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.

[16]  R. Berger,et al.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Meyer,et al.  Liver transplantation for cholangiocarcinoma: results in 207 patients. , 2000, Transplantation.

[18]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[19]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[20]  I. B. Borel Rinkes,et al.  Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.

[21]  M. Guba,et al.  DIFFERENTIAL EFFECTS OF SHORT‐TERM ACE‐ AND AT1‐RECEPTOR INHIBITION ON POSTISCHEMIC INJURY AND LEUKOCYTE ADHERENCE IN VIVO AND IN VITRO , 2000, Shock.

[22]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[23]  S. Baruchel,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.

[24]  C. Compton,et al.  Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1 , 1999, Nature Medicine.

[25]  J. Pouysségur,et al.  p70 S6 Kinase-mediated Protein Synthesis Is a Critical Step for Vascular Endothelial Cell Proliferation* , 1999, The Journal of Biological Chemistry.

[26]  D. McGiffin,et al.  Recurrence of bronchioloalveolar carcinoma in transplanted lungs. , 1999, The New England journal of medicine.

[27]  L. Overbergh,et al.  Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. , 1999, Cytokine.

[28]  M. Lagman,et al.  Cyclosporine induces cancer progression by a cell-autonomous mechanism , 1999, Nature.

[29]  J. Sato,et al.  MAP kinases, phosphatidylinositol 3‐kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor , 1999, Journal of cellular physiology.

[30]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[31]  S. Mahooti,et al.  Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. , 1998, Journal of cell science.

[32]  D. Ribatti,et al.  Antiangiogenesis by cyclosporine. , 1998, Experimental hematology.

[33]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[34]  S. Sehgal.  Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. , 1998, Clinical biochemistry.

[35]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[36]  M. Nardi,et al.  Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. , 1997, Investigative ophthalmology & visual science.

[37]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[38]  R. Abraham,et al.  Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. , 1995, Progress in cell cycle research.

[39]  I. Penn.  Occurrence of cancers in immunosuppressed organ transplant recipients. , 1994, Clinical transplants.

[40]  N. Sigal,et al.  Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. , 1990, Journal of immunology.

[41]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[42]  K Messmer,et al.  Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. , 1981, Cancer research.

[43]  M. Brattain,et al.  Establishment of mouse colonic carcinoma cell lines with different metastatic properties. , 1980, Cancer research.

[44]  R. Snow,et al.  Review of the Evidence. , 1964, Science.